A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.

The objective of this study is to collect additional data on safety, performance and
effectiveness of Phasix™ Mesh in subjects requiring primary ventral, incisional or
first-recurrent (protocol version 1.4)/multiply-recurrent (protocol version 2.0) hernia
repair in subjects at high risk for complications. Subjects at high risk are defined as
having 1 or more of the following co-morbidity conditions: body mass index (BMI) between
30-40 kg/m2, inclusive, active smokers, chronic obstructive pulmonary disease (COPD),
diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, low
pre-operative serum albumin, advanced age, or renal insufficiency.

Inclusion Criteria:

Subjects must have met all of the criteria listed below to be enrolled in the study:

1. Subject must have been 18 years of age or older 2. Subject or subject's legally
authorized representative must have given written informed consent 3. Subject must have
been diagnosed with primary ventral, incisional hernia or first time recurrent ventral or
incisional hernia (protocol version 1.4) 3. Subject must be diagnosed with primary ventral,
incisional hernia or multiply-recurrent (not to exceed 3 recurrences) ventral or incisional
hernia (protocol version 2.0) 4. Subject must have had a hernia greater than 10 cm2 and
≤350 cm2 5. Subject must have been willing to undergo initial ventral, incisional or first
recurrent incisional hernia repair using retro-rectus or onlay placement (using absorbable
suture) with or without Component Separation Technique (CST) (protocol version 1.4) 5.
Subject must be willing to undergo initial ventral, incisional or multiply-recurrent
incisional hernia repair using retro-rectus or onlay placement (using absorbable suture)
with or without Component Separation Technique (CST) (protocol version 2.0) 6. Subject met
the criteria for a Class I wound as defined by the CDC (Appendix 4 of the protocol) 7.
Subjects must have had 1 or more of the following pre-study conditions:

1. Body Mass Index (BMI) between 30-40 kg/m2, inclusive

2. Active smokers (if attempts to quit smoking within two weeks of surgery have failed
and the patient was still an active smoker at the time of surgery)

3. COPD presence on patient self-report

4. Diabetes mellitus

5. Immunosuppression

6. Coronary Artery Disease

7. Chronic corticosteroid use: greater than 6 months systemic use

8. Serum albumin less than 3.4 g/dL

9. Advanced age: 75 years or older

10. Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL

Exclusion Criteria:

Subjects were excluded from study enrollment if any of the following criteria were met:

1. Subject's hernia had recurred more than once (protocol version 1.4)

1. Subject has had 4 or more previous hernia repairs (of the index hernia) (protocol
version 2.0)

2. The subject had peritonitis

3. The subject was on or suspected to be placed on chemotherapy medications during any
part of the study

4. The subject's Body Mass Index (BMI) was greater than 40 kg/m2

5. The subject had cirrhosis of the liver and/or ascites

6. Subject was American Society of Anesthesiology Class 4 or 5

7. Subject was known to be infected with human immunodeficiency virus (HIV)

8. Subject had a life expectancy of less than 2 years at the time of enrollment

9. Subject had any condition that, in the opinion of the Investigator, precluded the use
of the study device, precluded the subject from completing the follow-up requirements

10. Subject's hernia repair utilized intraabdominal mesh placement

11. Subject had a surgical wound classified as Class II (Clean-Contaminated), Class III
(Contaminated) or Class IV (Dirty-Contaminated) as defined by the CDC (Appendix 4 of
the protocol)

12. Subject had an active or latent systemic infection

13. Subject required surgical bridge repair as the sole repair

14. Subject was pregnant or had plans to become pregnant during the study period or was
breastfeeding

15. Subject had enrolled in another clinical study within the last 30 days

16. Subject was part of the site personnel directly involved with this study

17. Subject had a known allergy to the test device or component materials (patients with
known allergies to tetracycline hydrochloride or kanamycin sulfate were avoided).